IL-12 Contributes to the Development of Asthma by Targeting HIF-1α/NLRP3 Pathway through Runx3

Abstract

<b><i>Introduction:</i></b> The aim of the study was to determine the role and mechanism of runt-related transcription factor 3 (Runx3) in the development of asthma. <b><i>Methods:</i></b> An asthma mouse model was constructed and validated by hematoxylin-eosin analysis of lung tissue and noninvasive enhanced pause (Penh) evaluation of airway hyperresponsiveness. Then, the levels of Runx3 and interleukin (IL)-12 in peripheral blood and lung tissue were detected by enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry. By use Runx3<sup>+/−</sup> mice, the effect of Runx3 downregulation on ovalbumin (OVA)-induced asthma was investigated. After stimulated by different doses of IL-12, the expressions of Runx3, hypoxia inducible factor-1α (HIF-1α), and NOD-like receptor thermal protein domain associated protein 3 (NLRP3) in BEAS-2B cells were tested through Western blot and immunofluorescence. Subsequently, BEAS-2B cells treated with 20 ng/mL IL-12 were divided into control, Runx3 overexpression negative control, Runx3 overexpression, HIF-1α inhibitor, and Runx3 overexpression + HIF-1α agonist groups. The Western blot, immunofluorescence, and ELISA indicators were tested repeatedly. <b><i>Results:</i></b> The increased number of inflammatory cells and Penh value confirmed the success of the asthma mouse model. IL-12 expression was significantly increased, and Runx3 was reduced in asthma mice compared with wild-type mice. Meanwhile, the level of immunoglobulin E (IgE) in serum, cytokines in bronchoalveolar lavage fluid, and IL-12, HIF-1α, NLRP3 in the lung were significantly elevated in Runx3<sup>+/−</sup> mice. With the increase of IL-12 concentration, Runx3 protein expression decreased, while HIF-1α and NLRP3 expression increased. Further mechanistic studies suggest that Runx3 ameliorates IL-12-induced BEAS-2B injury by inhibiting HIF-1α/NLRP3 pathway. <b><i>Conclusion:</i></b> These results suggested that IL-12 contributes to the development of asthma by targeting HIF-1α/NLRP3 pathway through Runx3, thus providing a novel strategy for asthma therapy.

Demonstrating the immunostimulatory and cytokine‐augmentation effects of bacterial ghosts on natural killer cells and Caenorhabditis Elegans

“…A time‐dependent treatment of NK‐92 cells was done using BG_IL12 particles containing 20 ng/mL of IL‐12 (corresponding to 488.28 ng/mL of BGs as per binding efficiency), and was compared with equivalent concentrations of free BG (488.28 ng/mL) and IL‐12 (20 ng/mL). Earlier reports on cytokine combination therapy have suggested 20 ng/mL as a sufficient dosage for IL‐12 (Guia et al, 2008; Sun et al, 2022). Hence, we decided to follow the same in our study.…”

The Perspective of Using Flow Cytometry for Unpuzzling Hypoxia-Inducible Factors Signalling

“…In chronic obstructive pulmonary disease (COPD), HIF-1 increases and causes hypersecretion of the mucus in the airways through the epidermal growth factor receptor (EGFR) [57]. Inhibition of HIF-1 was found to be beneficial in the treatment of asthma [58].…”